- Home
- RBOT vs CTXR Comparison
RBOT vs CTXR Comparison
Compare RBOT & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBOT | CTXR |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 16.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RBOT | CTXR |
|---|---|---|
| Price | $2.13 | $0.78 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $7.00 | $6.00 |
| AVG Volume (30 Days) | 161.6K | ★ 282.2K |
| Earning Date | 03-16-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.81 | $0.63 |
| 52 Week High | $16.35 | $2.97 |
Technical Indicators
Market Signals| Indicator | RBOT | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 39.07 | 39.32 |
| Support Level | $2.02 | $0.73 |
| Resistance Level | $2.30 | $0.84 |
| Average True Range (ATR) | 0.23 | 0.05 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 12.24 | 38.38 |
Price Performance
Historical ComparisonAbout RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.